title: alphaB-crystallin is phosphorylated during myocardial infarction: involvement of platelet-derived growth factor-BB.
abstract: alphaB-crystallin is the most abundant low-molecular-weight heat shock protein in heart and recent studies have demonstrated that it plays a cardioprotective role during myocardial infarction both in vivo and in vitro. On the other hand, platelet-derived growth factor (PDGF), a potent serum mitogen, has been reported to improve cardiac function after myocardial infarction. In the present study, using a mouse myocardial infarction model, we investigated whether alphaB-crystallin is phosphorylated during myocardial infarction and the implication of PDGF-BB. Phosphorylation of alphaB-crystallin at Ser-59 was time dependently induced and plasma PDGF-BB levels were concomitantly increased. Moreover, PDGF-BB-stimulated phosphorylation of alphaB-crystallin was suppressed by SB203580, a specific inhibitor of p38 mitogen-activated protein (MAP) kinase, in primary cultured cardiac myocytes. Our results indicate that PDGF-BB induces phosphorylation of alphaB-crystallin via p38 MAP kinase during myocardial infarction.
authors.affiliation: Department of Pharmacology, Gifu University Graduate School of Medicine, Japan.
authors.forename: En
authors.initials: E
authors.lastname: Shu
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Matsuno
authors.forename: Shigeru
authors.initials: S
authors.lastname: Akamastu
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kanno
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Suga
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakajima
authors.forename: Akira
authors.initials: A
authors.lastname: Ishisaki
authors.forename: Shinji
authors.initials: S
authors.lastname: Takai
authors.forename: Kanefusa
authors.initials: K
authors.lastname: Kato
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kitajima
authors.forename: Osamu
authors.initials: O
authors.lastname: Kozawa
mesh_terms: D000818:Animals; D000077214:Becaplermin; D015153:Blotting, Western; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D005786:Gene Expression Regulation; D006352:Heart Ventricles / Q000473:pathology; D007093:Imidazoles / Q000494:pharmacology; D007150:Immunohistochemistry; D020935:MAP Kinase Signaling System; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009203:Myocardial Infarction / Q000378:metabolism*; D009206:Myocardium / Q000473:pathology; D010766:Phosphorylation; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D020574:Proto-Oncogene Proteins c-sis; D011725:Pyridines / Q000494:pharmacology; D012694:Serine / Q000378:metabolism; D013997:Time Factors; D038203:alpha-Crystallin B Chain / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D005419:Flavonoids; D007093:Imidazoles; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011725:Pyridines; D038203:alpha-Crystallin B Chain; D000077214:Becaplermin; D012694:Serine; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one